Chloramphenicol
Brand names: Kemicetine (systemic), Chloramphenicol eye drops/ointment
Chloramphenicol is a broad-spectrum amphenicol antibiotic. Systemic use is now reserved for serious infections where safer alternatives are unsuitable, while topical eye and ear preparations remain in common use for superficial bacterial infection.
Adult dose
Paediatric dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Children: equivalent of 50 mg/kg chloramphenicol per day in divided doses every 6 hours; observe carefully for signs of toxicity. Neonates and premature infants: total 25 mg/kg/day in 4 equal doses at 6-hour intervals; risk of neonatal Grey syndrome. Verify against a children's formulary.
Contraindications
- Previous history of sensitivity and/or toxic reaction to chloramphenicol
- Pregnancy and breast-feeding
- Trivial infections, or where not indicated (e.g. colds, influenza, throat infections), or as prophylaxis
Side effects
- Bone marrow depression / blood dyscrasias (aplastic anaemia, agranulocytosis, pancytopenia, thrombocytopenic purpura)
- Neonatal Grey syndrome
- Peripheral neuritis; optic neuritis; blurred/transient loss of vision
- Vomiting, diarrhoea, nausea, dry mouth
- Fungal superinfection; urticaria
Interactions
- Other drugs that may cause bone marrow depression — concurrent therapy should be avoided
- Monitor serum levels particularly in neonates/premature infants, elderly, renal or hepatic disease, and with other interacting drugs
Clinical monograph
How it works
It binds reversibly to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase, thereby blocking protein synthesis; it is usually bacteriostatic.
Prescribing in practice
- Systemic chloramphenicol can cause dose-independent, irreversible aplastic anaemia and dose-related reversible bone-marrow suppression, so systemic courses must be kept as short as possible with close haematological supervision.
- Avoid in neonates where it can precipitate grey baby syndrome from impaired conjugation and reduced clearance.
- It inhibits hepatic cytochrome P450 enzymes and can raise levels of warfarin, phenytoin and sulfonylureas.
Monitoring
Monitor the full blood count regularly during systemic therapy, and consider plasma-concentration monitoring in neonates, infants and patients with hepatic impairment.
Counselling the patient
- Report any unexplained fever, sore throat, bruising or bleeding promptly as these may signal blood disorders.
- Complete the full course even once you feel better.
Evidence & guidelines
Chloramphenicol is a long-established agent whose haematological toxicity is documented in MHRA safety guidance and standard prescribing references.
Reference: PHE Meningitis Antibiotic Guidelines; NICE NG 41 Meningitis; WHO Essential Medicines List 2023; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steinhart Model for Acute Heart Failure in Undifferentiated Dyspnoea · Heart Failure
- FOUR Score (Full Outline of UnResponsiveness) · Consciousness
- SIRS Criteria and Sepsis Definition · Sepsis
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- Dengue Severity Classification (WHO 2009) · Tropical Infections
- Malaria Severity Assessment (WHO Criteria) · Tropical Infections